Inventor · disambiguated record
Carlos G. Perez-Garcia
Also filed as: PEREZ-GARCIA CARLOS G · PEREZ-GARCIA CARLOS GUSTAVO
7 granted patents·4 pending applications·12 citations·filing 2018–2024
78Inventor score
Top patents by PatentIndex Score
11 records- 0190US11685906B2Compositions and methods for treating ornithine transcarbamylase deficiencyARCTURUS THERAPEUTICS INC·Filed 2019·Granted Jun 27, 2023·4 cites·25 claims
- 0289US11015204B2Synthesis and structure of high potency RNA therapeuticsARCTURUS THERAPEUTICS INC·Filed 2018·Granted May 25, 2021·6 cites·28 claims
- 0385US12070509B2Nucleic acids and methods of treatment for cystic fibrosisARCTURUS THERAPEUTICS INC·Filed 2021·Granted Aug 27, 2024·1 cites·34 claims
- 0484US12398379B2Compositions and methods for treating ornithine transcarbamylase deficiencyARCTURUS THERAPEUTICS INC·Filed 2023·Granted Aug 26, 2025·0 cites·20 claims
- 0578US11377643B2Therapeutics for glycogen storage disease type IIIULTRAGENYX PHARMACEUTICAL INC·Filed 2018·Granted Jul 5, 2022·1 cites·20 claims
- 0672US2025049950A1Nucleic acids and methods of treatment for cystic fibrosisARCTURUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0769US12509698B2Synthesis and structure of high potency RNA therapeuticsARCTURUS THERAPEUTICS INC·Filed 2021·Granted Dec 30, 2025·0 cites·18 claims
- 0866US2022340886A1Therapeutics for glycogen storage disease type iiiULTRAGENYX PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 0960US2023159449A1Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosisARCTURUS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1052US2022096520A1Modified proteins and associated methods of treatmentARCTURUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1148US11939600B2Compositions and methods for treating phenylketonuriaARCTURUS THERAPEUTICS INC·Filed 2018·Granted Mar 26, 2024·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Carlos G. Perez-Garcia files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →